Beyond BCMA: The next wave of CAR T cell therapy in multiple myeloma Review
| Authors: | Miller, K.; Hashmi, H.; Rajeeve, S. |
| Review Title: | Beyond BCMA: The next wave of CAR T cell therapy in multiple myeloma |
| Abstract: | Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CAR T cell therapy are underway. Meanwhile, other viable antigenic targets are being pursued, including G protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocytic activation molecule family member 7 (SLAMF7), and CD38, among others. CAR T cells targeting these antigens, alone or in combination with anti-BCMA approaches, appear to be highly promising as they move from preclinical studies to early phase clinical trials. This review summarizes the current data with novel CAR T cell targets beyond BCMA that have the potential to enter the treatment landscape in the near future. Copyright © 2024 Miller, Hashmi and Rajeeve. |
| Keywords: | unclassified drug; review; t lymphocyte; cell survival; multiple myeloma; protein p53; immunological tolerance; immunotherapy; chimeric antigen receptor; g protein coupled receptor; drug binding; syndecan 1; phase 3 clinical trial (topic); phase 1 clinical trial (topic); april protein; human; b cell maturation antigen; chimeric antigen receptor t-cell immunotherapy; car t cell therapy; ciltacabtagene autoleucel; idecabtagene vicleucel; non-bcma; g protein-coupled receptor class c group 5 member d; signaling lymphocytic activation molecule |
| Journal Title: | Frontiers in Oncology |
| Volume: | 14 |
| ISSN: | 2234-943X |
| Publisher: | Frontiers Media S.A. |
| Date Published: | 2024-01-01 |
| Start Page: | 1398902 |
| Language: | English |
| DOI: | 10.3389/fonc.2024.1398902 |
| PROVIDER: | scopus |
| PMCID: | PMC11116580 |
| PUBMED: | 38800372 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work